Bavarian Nordic A/S (BAVA.CO)
| Previous Close | 149.50 |
| Open | 149.50 |
| Bid | 144.45 x 0 |
| Ask | 144.60 x 0 |
| Day's Range | 143.75 - 149.55 |
| 52 Week Range | 125.55 - 222.00 |
| Volume | |
| Avg. Volume | 544,070 |
| Market Cap | 11.236B |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | 7.51 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Reuters
UPDATE 2-US CDC recommends routine use of Bavarian Nordic mpox vaccine for adults at risk
Danish pharmaceutical company Bavarian Nordic said on Wednesday a U.S. Centers for Disease Control and Prevention panel has voted in favor of recommending the routine use of Jynneos vaccine for adults at risk of mpox. The CDC's Advisory Committee on Immunization Practices (ACIP) voted to recommend that individuals 18 years and older with certain risk factors should receive two doses of Jynneos. The panel had previously recommended the vaccine for individuals at risk of mpox only during an outbreak, Bavarian said.
- Reuters
UPDATE 1-Bavarian Nordic ends RSV vaccine programme after poor trial results
Denmark-based Bavarian Nordic said on Saturday it was ending its respiratory syncytial virus (RSV) vaccine programme as its Phase 3 clinical trial did not meet all the primary goals of preventing lower respiratory tract disease. RSV is a common respiratory virus that usually causes mild, cold-like symptoms but can also lead to serious illness and hospitalisation. The market for RSV vaccines could exceed $10 billion by 2030, according to analysts.
- Reuters
UPDATE 1-Those at high risk of mpox should get 2 doses of Bavarian Nordic vaccine, US CDC says
The U.S. Centers for Disease Control and Prevention is urging people at high risk of mpox to get two doses of Bavarian Nordic's Jynneos vaccine, based on new evidence from a U.S. study showing that the regimen is more effective at preventing infection than one shot. The study, published on Thursday, offered some of the first evidence on the efficacy of the Jynneos vaccine, which was deployed last year during a global outbreak of mpox that affected more than 30,000 people in the United States. The study of the vaccine's real-world use, conducted between Aug. 19, 2022 and March 31, 2023 among 917 people, showed it was 85.9% effective overall in preventing disease after two doses, compared with 75.2% after one dose.
